High-performing organizations know that sustainable safety around infection control is not achieved through compliance alone, but through a deep-rooted culture of vigilance, ownership, and continuous improvement. That culture starts with leadership commitment.

Trump administration releases 2026 budget, President Trump to boost domestic pharmaceutical manufacturing, Rite Aid declares bankruptcy again.

This week’s graphic illustrates how Epic has continued to expand its lead in the electronic health record (EHR) market over its rival Oracle Health, which acquired Cerner in 2022.

Two out of every five healthcare providers—just over 40%—in the United States are now non-physician, advanced practice providers.

Daily patient volumes decreased due to declines in flu and other seasonal infectious diseases, contributing to a decline in hospital care expenses despite elevated overall expenses.

Why are hospitals unable to efficiently fill their appointment slots, even in the face of very significant demand? Lessons from the airlines on how they fill seats can help provide solutions to this problem.

This week’s graphic highlights new Gallup survey data and Bureau of Labor Statistics inflation data to consider growing healthcare affordability challenges.

Supreme Court rules in favor of HHS in DSH payment case, vaccine testing to change, Aetna to exit ACA marketplace.

Senior healthcare leaders and board members routinely ask us the following two questions.

Hospitals continue to lose significant money on employing physicians, and the original goals of care coordination and efficiency haven't materialized. Rising costs, declining reimbursement advantages, overutilization of low-margin services and administrative burdens are factors behind these unsustainable losses.

As Medicaid cuts look increasingly likely per Congress’ recently-passed budget plan, this week’s graphic uses survey data from KFF to take stock of the public’s view of the program.

UnitedHealth Group stock drops, eight artificial food dyes to be phased out, Eli Lilly oral GLP-1 pill has promising Phase 3 result